These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 20134115

  • 1. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M, Masunaga K, Nagata T, Yono M, Homma Y.
    J Pharmacol Sci; 2010; 112(2):128-34. PubMed ID: 20134115
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Local effects of antimuscarinics.
    Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, Yoshimura N.
    Urol Clin North Am; 2006 Nov; 33(4):511-8, ix-x. PubMed ID: 17011387
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
    Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, Van Der Aa F, Cornu JN.
    Eur Urol; 2019 Jun; 75(6):988-1000. PubMed ID: 30922690
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic receptor targets for lower urinary tract dysfunction.
    Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, Tyagi P.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):437-48. PubMed ID: 18034230
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
    Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, Finazzi-Agrò E.
    Urol Int; 2012 Jun; 89(1):1-8. PubMed ID: 22738896
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
    Dobrek Ł, Juszczak K, Wyczółkowski M, Thor PJ.
    Acta Pol Pharm; 2011 Jun; 68(6):807-21. PubMed ID: 22125944
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM, Giannantoni A.
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [Abstract] [Full Text] [Related]

  • 19. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.
    Andersson KE.
    Int J Clin Pract Suppl; 2006 Dec; (151):8-16. PubMed ID: 17169005
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.